Lymphoma Clinical Trials in Salt Lake City

Showing 461-467 of 467 trials

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

LymphomaLeukemiaCancer

MedImmune LLC80 participantsStarted Feb 2005

Los Angeles, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

COMPLETEDPhase 2371 miles

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Mantle Cell Lymphoma

Millennium Pharmaceuticals, Inc.152 participantsStarted Jun 2003

Birmingham, Alabama, United States • Berkeley, California, United States • Duarte, California, United States +32 more locations

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma Trials in Other Cities

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Other Conditions in Salt Lake City